These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28533049)

  • 1. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
    Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
    Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
    Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
    Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
    Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
    Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
    Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
    Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
    Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
    Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
    Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
    Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
    Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
    El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
    Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
    Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
    Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
    Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
    PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
    Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
    Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
    Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of change in FEV
    Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
    Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
    Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
    Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
    Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.